Core Viewpoint - The company, Brainstorm Aurora-B (06681), has seen its stock price increase by over 4%, currently trading at 4.83 HKD with a transaction volume of 48.71 million HKD, following the announcement of a strategic partnership with Macau Kiang Wu Hospital to enhance digital health services for cognitive disorders [1] Group 1 - The company’s subsidiary, Brainstorm Aurora Medical Technology (Macau) Limited, has signed a cooperation agreement with Macau Kiang Wu Hospital to provide digital AI technology services for brain health [1] - The partnership aims to establish a comprehensive health management model covering "hospital-community-home" for cognitive disorder screening, assessment, training, and management in the Macau region [1] - The board believes this collaboration sets a benchmark for the group and opens up the Greater Bay Area market, marking the first flagship project for the group’s digital therapy in the Hong Kong-Macau region [1] Group 2 - The collaboration enriches the company's ecosystem alliance with authoritative medical institutions, complementing a recent national-level project partnership with the National Rehabilitation Aids Research Center under the Ministry of Civil Affairs [1] - This initiative aims to promote the standardization and large-scale application of cognitive digital therapies [1]

脑动极光-B(06681)发布公告，公司的间接全资附属公司-脑动极光医学科技数智(澳门)有限公司(脑动极 光澳门)，已于近期与澳门镜湖医院正式签署《脑健康数字AI技术服务合作协议》。双方将围绕认知障 碍的数字筛查、评估、训练及全程健康管理，在澳门地区建立长期战略合作关系，共同构建覆盖"医院- 社区-家居"的全链条脑健康服务新模式。 根据该协议，本次合作将围绕以下核心内容展开：1.共建"健脑中心"与服务体系：双方将基于集团 的"六六脑科学健脑云服务"平台，在镜湖医院内设立并运营"健脑中心"。该中心将提供从早期筛查、精 准评估到数字化认知训练及病程随访的一站式服务，构建镜湖医院内部"早期筛查-精准诊断-多学科干 预-社区居家延伸"的全周期管理模式。 2.覆盖全年龄段的诊疗服务：服务对象包括60岁及以上的认知障碍风险人群及患者，以及3至18岁有神 经发育障碍的儿童患者。可根据医生处方，提供院内或居家形式的数字疗法治疗服务。 3.确保数据安全与合规：所有服务产生的数据将严格遵循澳门相关法律法规，在澳门本地进行服务器部 署与数据存储，实现数据完全本地化，不传输出境，保障信息安全与合规性。 4.联合科研与学术交流：双方将 ...

Core Insights - The company, Taimei Medical Technology, has recently achieved significant milestones, including the global approval of the first load ultrasound echocardiography indication and the first domestic tumor electric field therapy device, bringing the total number of approved projects to 58 across various medical fields [1][2]. Group 1: Project Approvals and Recognition - The IRC team at Taimei Medical Technology has received high recognition from clients for their professionalism and rigorous approach during clinical trials, ensuring accuracy and reliability in evaluation results [2]. - The increasing number of approved projects reflects the company's strong capabilities in navigating regulatory requirements and maintaining high standards in clinical research [1][2]. Group 2: Regulatory Inspection and Compliance - The National Medical Products Administration (NMPA) has raised its inspection standards, focusing on critical aspects that affect the accuracy and independence of image assessments [3][4]. - The eImage system developed by Taimei Medical Technology is highlighted as a crucial tool for meeting these regulatory demands, providing comprehensive tracking and evidence during inspections [3]. Group 3: Inspection Process and Best Practices - The inspection process involves notifying sponsors, executing on-site inspections, and summarizing findings, which requires thorough preparation and documentation [4][5]. - Key areas of focus during inspections include the traceability of case evaluations and adherence to imaging-related protocols [6][7]. Group 4: Team Expertise and Service Strength - The IRC team boasts a strong professional background, with 100% of imaging quality control personnel having medical imaging expertise and all efficacy evaluators holding medical qualifications [8]. - Taimei Medical Technology has established a comprehensive service system, with over 500 project experiences, positioning itself as a reliable partner in the pharmaceutical innovation journey [8].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部 或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 Mediwelcome Healthcare Management & Technology Inc. 麥迪衛康健康醫療管理科技股份有限公司 （於開曼群島註冊成立的有限公司） （股份代號：2159） 內幕消息 關於潛在收購事項之諒解備忘錄 本 公 告 乃 由 麥 迪 衛 康 健 康 醫 療 管 理 科 技 股 份 有 限 公 司（「本公司」，連 同 其 附 屬 公 司，統 稱「本集團」）根 據 香 港 聯 合 交 易 所 有 限 公 司 證 券 上 市 規 則（「上市規則」）第 13.09條及香港法例第571章證券及期貨條例第XIVA部 項 下 內 幕 消 息 條 文（定 義 見 上 市 規 則）作 出。 諒解備忘錄僅反映各訂約方對潛在收購事項之初步共識，除上文所載有關排他期、 盡 職 審 查 和 終 止 的 條 款，以 及 有 關（其 中 包 括 ...

Core Viewpoint - Yunnan Yibao Medical Technology Co., Ltd. has been established with a registered capital of 3 million RMB, fully owned by Yibao Technology (Shanghai) Co., Ltd. [1] Company Information - The legal representative of Yunnan Yibao Medical Technology Co., Ltd. is Luo Han [1] - The registered capital of the company is 3 million RMB [1] - The company is located in Hongshan South Road Community, Wuhua District, Kunming City, Yunnan Province [2] - The company is classified as a limited liability company (sole proprietorship) [2] - The business license allows the company to operate until December 24, 2025, with no fixed term thereafter [2] Shareholder Information - Yibao Technology (Shanghai) Co., Ltd. holds 100% of the shares in Yunnan Yibao Medical Technology Co., Ltd. [2] Business Scope - The business scope includes medical research and experimental development, technical services, technology development, consulting, and transfer [2] - Additional services include internet data services, enterprise management consulting, information system integration, electronic product sales, and software development [2] - The company is also involved in health services, remote health management, and health consulting (excluding diagnostic services) [2] - Certain activities require approval from relevant authorities, including internet information services and medical device internet information services [2]

Core Insights - The second "Haiyi Hui Medical Technology Innovation Ecosystem Conference" was held in Beijing, focusing on AI and technology's role in advancing healthcare in China by 2030 [1] - The conference aimed to address the low medical achievement conversion rate in China, which has been below 8%, highlighting the need for collaboration across research, clinical validation, and industrial transformation [2][3] Group 1: Medical Innovation and Collaboration - The establishment of Haiyi Hui aims to create a collaborative platform for medical and industrial transformation, linking over 100 research institutions and hospitals to conduct more than 600 distributed clinical trials [2] - The conference emphasized the importance of aligning research with clinical needs to overcome barriers in the medical innovation process [3] - A call for an open and collaborative mechanism was made to break down barriers in data, disciplines, and institutions, ensuring a free flow of innovative resources [2] Group 2: Accelerating Technology Transfer - The conference highlighted the need for a transformation system that integrates enterprises, clinical needs, and deep collaboration between academia and industry to enhance the speed of technology transfer [4] - Haiyi Hui announced over ten groundbreaking technologies in various fields, showcasing a complete cycle from technological breakthroughs to clinical application [5] - The integration of AI in healthcare is seen as a key driver for enhancing service accessibility, precision, and efficiency [6] Group 3: Talent Development and Social Responsibility - Haiyi Hui has initiated a "Science and Technology Elite Cultivation Program" to support young researchers and innovation teams, focusing on rare and difficult diseases [7] - The program aims to build a collaborative training system that connects basic research, clinical practice, and technology transfer [7] - The establishment of the "China Youth Entrepreneurship and Employment Foundation" aims to strengthen the cultivation of composite talents in the healthcare sector [7] Group 4: Strategic Vision and Future Directions - Haiyi Hui is exploring pathways to drive medical industrial transformation through ecological forces and AI integration for high-quality development in the health industry [8] - The platform has established mechanisms for integrating clinical, research, and industrial efforts, as well as channels for technology, capital, and market transformation [9] - The future of medical innovation is viewed as a success of the ecosystem rather than individual technologies, with aspirations to integrate into a larger domestic and international cycle [9]

Core Points - The company has approved the addition and revision of internal management systems to enhance operational standards and governance structure [1][22] - The company plans to appoint Zhonghui Certified Public Accountants as its financial and internal control audit institution for the year 2025 [5][23] Group 1: Internal Management System Updates - The company held its 37th meeting of the fourth board of directors on November 24, 2025, where it approved the addition of the "Management System for the Departure of Directors and Senior Management" and revisions to existing internal management systems [1][22] - The revised "Selection System for Accounting Firms" has been approved by the board's audit committee [2][22] - The "Financing Decision-Making System" will require approval from the shareholders' meeting [3][22] Group 2: Audit Institution Appointment - The company intends to continue employing Zhonghui Certified Public Accountants as its financial and internal control audit institution for 2025, pending approval from the shareholders' meeting [5][23] - Zhonghui Certified Public Accountants has a history of providing securities services and has been operational since December 2013, with a total revenue of 1.01434 billion yuan in 2024, of which 899.48 million yuan was from audit services [6][7][8] - The audit fees for 2025 are capped at 900,000 yuan, with 700,000 yuan allocated for financial audit and 200,000 yuan for internal control audit, reflecting a change of less than 20% from the previous year [14][24]

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has requested additional documentation from Weimai regarding its overseas listing application, focusing on employee stock ownership plans and foreign exchange registration procedures [1][2][3] Group 1: Regulatory Requirements - CSRC has asked Weimai to clarify the foreign investment and foreign exchange management procedures related to its subsidiaries, including Qiushi Technology and others [1] - The commission requires a detailed explanation of the acquisition costs, pricing basis, and tax obligations related to the purchase of various companies, including Hangzhou Weir and Ronghai Insurance [1][2] - Weimai must provide information on its employee incentive programs, including the involvement of external consultants and the establishment of employee stock ownership platforms [2] Group 2: Company Overview - Weimai is recognized as a pioneer and leader in AI-driven full-cycle management services in China, linking hospitals, doctors, and patients to enhance the healthcare service value chain [3] - According to projected revenues for 2024, Weimai ranks among the top three full-cycle management service providers in China and is the largest patient-oriented AI-enabled service provider [3] - The company's services encompass the entire health management process for patients, from pre-treatment to post-treatment [3]

Summary of Key Points Core Viewpoint - 医渡科技 has been actively repurchasing its shares, indicating confidence in its market position and future prospects [1] Group 1: Share Buyback Activity - On October 17, 医渡科技 spent HKD 1.013 million to repurchase 181,000 shares [1] - This week, the company has conducted three buybacks totaling approximately 2.685 million shares, with a total expenditure exceeding HKD 15.6 million [1] - Since September 26, the company has executed five buybacks, amounting to around 3.373 million shares and nearly HKD 20 million in total [1] Group 2: Southbound Capital Inflows - On October 14, southbound funds net purchased HKD 34.7273 million worth of 医渡科技 shares, marking the highest net inflow since September 1, 2025 [1] - The net buying has continued for three consecutive days, with a cumulative net purchase of HKD 57.79 million [1] Group 3: Product Development and Market Support - Recently, the world's first topical treatment for proliferative superficial infantile hemangioma, Timolol Maleate Gel, has been approved for market release [1] - 医渡科技 provided critical market research and project analysis services that supported the drug's development and market entry [1]

Core Viewpoint - The event focused on the globalization of medical innovation in China, highlighting the integration of AI in healthcare services and the transformation of the industry towards efficiency-driven competition [1][6]. Group 1: AI Integration in Healthcare - Huamei Haolian positions itself as a "one-stop AI digital healthcare service platform," aiming to efficiently integrate medical resource supply and demand through a B2B2C model [2]. - The company emphasizes a "data-driven service upgrade" approach, showcasing a development trend of "point - line - network" in healthcare services [3]. - AI has significantly improved efficiency in report interpretation, reducing the time from approximately 6 hours per case to under 30 minutes through an "AI + human professional review" model [2][3]. Group 2: Comprehensive Health Management - AI extends to full-cycle health management, transforming user health data into understandable content and providing personalized intervention suggestions for chronic disease patients [3]. - The "Dr. Hua" AI system is central to creating a closed-loop service ecosystem, automatically matching users with appropriate healthcare providers based on their needs [3]. - The integration of AI allows for compliance in sharing health data, facilitating value collaboration among healthcare, insurance, and users [3]. Group 3: Driving Value through Collaboration - AI acts as a "demand detector" in service innovation, identifying industry pain points and automating standard service processes to respond quickly to healthcare needs [5]. - In service delivery, AI matches users with healthcare professionals based on health records and needs, significantly reducing wait times and enhancing service accessibility [5]. - The long-term goal is to create a "data-driven ecological barrier" that empowers healthcare institutions and partners while ensuring technology is effectively applied in various scenarios [5]. Group 4: Industry Transformation and Future Outlook - AI is shifting the healthcare service industry from a focus on resource competition to efficiency competition, promoting quality over quantity [6]. - Companies that can effectively implement AI in practical scenarios are expected to emerge as core players, while those relying on low-cost strategies may be eliminated [6]. - The future vision for AI in healthcare is to serve as a "connecting link," breaking down barriers between service segments and enabling personalized healthcare experiences for individuals [6].